Rocket Pharmaceuticals Prices Public Offering of Common Stock

NEW YORK–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading
U.S.-based multi-platform gene therapy company, today announces the
pricing of an underwritten public offering of 4,500,000 shares of its
common stock at a public offering price of $17.50 per share. The gross
proceeds to Rocket from the offering are expected to be $78,750,000,
before deducting the underwriting discounts and commissions and other
offering expenses. Rocket has granted the underwriters a 30-day option
to purchase up to an additional 675,000 shares of its common stock.

All the shares in the offering are to be sold by Rocket. The offering is
expected to close on or about April 18, 2019, subject to satisfaction of
customary closing conditions. Rocket intends to use the net proceeds
from this offering to further fund the development of its pipeline of
gene therapies for rare diseases, to accelerate the buildout of in-house
manufacturing capabilities, and for general corporate purposes.

SVB Leerink, Evercore ISI and William Blair are acting as the
joint-bookrunning managers and Oppenheimer & Co. is acting as lead
manager for the public offering.

The public offering is being made by Rocket pursuant to an effective
shelf registration statement on Form S-3 that was previously filed with
the U.S. Securities and Exchange Commission (the “SEC”) and declared
effective by the SEC. A final prospectus supplement relating to and
describing the terms of this offering will be filed with the SEC. When
available, copies of the final prospectus supplement and the
accompanying prospectus relating to these securities may be obtained
from SVB Leerink LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525,
ext. 6132, or by email;
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd
Street, 36th Floor, New York, NY 10055, by telephone at (888) 474-0200,
or by email at;
and William Blair & Company, L.L.C., Attention: Prospectus Department,
150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800)
621-0687, or by email at
You may also obtain these documents free of charge by visiting the SEC’s
website at

This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or

Forward-looking Statements

Various statements in this release concerning Rocket’s future
expectations, plans and prospects, including without limitation,
Rocket’s expectations regarding the consummation of the offering and the
satisfaction of customary closing conditions with respect to the
offering and the anticipated use of the net proceeds of the offering,
may constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act of
1995 and other federal securities laws and are subject to substantial
risks, uncertainties and assumptions. You should not place reliance on
these forward-looking statements, which often include words such as
“anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”
“seek,” “should,” “suggest,” “target,” “will,” “will give,” “would,” or
similar terms, variations of such terms or the negative of those terms.
Although Rocket believes that the expectations reflected in the
forward-looking statements are reasonable, Rocket cannot guarantee such
outcomes. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including, without limitation, changes as a result of market
conditions or for other reasons, the risk that the offering will not be
consummated, and the impact of general economic, industrial or political
conditions in the United States or internationally, as well as those
risks more fully discussed in the section entitled “Risk Factors” in
Rocket’s Annual Report on Form 10-K for the year ended December 31,
2018. Accordingly, you should not place undue reliance on these
forward-looking statements. All such statements speak only as of the
date made, and Rocket undertakes no obligation to update or revise
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.


Claudine Prowse, Ph.D.
SVP Corporate Development and IRO
Pharmaceuticals, Inc.
The Empire State Building, Suite 7530
York, NY 10118